Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. LMT
9. SPY
10. SBUX

Go back to Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 1c

Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results

May 6, 2015 4:01 PM EDT

WASHINGTON, May 6, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2015.

"The first quarter of 2015 was a record quarter for product sales driven by HETLIOZ and Fanapt.  As we are just at the beginning of accessing the 80,000 Non-24 patients in the U.S., the growth potential for HETLIOZ remains ahead.  Similarly, the expanded patent exclusivity for Fanapt underscores the growth potential of this product through the coming decade and beyond.  We are looking to further drive revenue growth through... More